MEDLIB-L Archives

April 2020, Week 4


Options: Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Richard James <[log in to unmask]>
Reply To:
Richard James <[log in to unmask]>
Wed, 22 Apr 2020 09:08:07 -0400
text/plain (98 lines)
Some results in Embase:

Reducing mortality from 2019-nCoV: host-directed therapies should be an
The Lancet 2020 395 :10224 (e35 - e36)

Translated Title
Treatment of Middle East Respiratory Syndrome with a combination of
lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for
a randomized controlled trial
Trials 2018 19 :1 Article Number 81
Translated Abstract
Background: It had been more than 5 years since the first case of Middle
East Respiratory Syndrome coronavirus infection (MERS-CoV) was recorded,
but no specific treatment has been investigated in randomized clinical
trials. Results from in vitro and animal studies suggest that a combination
of lopinavir/ritonavir and interferon-β1b (IFN-β1b) may be effective
against MERS-CoV. The aim of this study is to investigate the efficacy of
treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b
provided with standard supportive care, compared to treatment with placebo
provided with standard supportive care in patients with
laboratory-confirmed MERS requiring hospital admission. Methods: The
protocol is prepared in accordance with the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials) guidelines. Hospitalized
adult patients with laboratory-confirmed MERS will be enrolled in this
recursive, two-stage, group sequential, multicenter, placebo-controlled,
double-blind randomized controlled trial. The trial is initially designed
to include 2 two-stage components. The first two-stage component is
designed to adjust sample size and determine futility stopping, but not
efficacy stopping. The second two-stage component is designed to determine
efficacy stopping and possibly readjustment of sample size. The primary
outcome is 90-day mortality. Discussion: This will be the first randomized
controlled trial of a potential treatment for MERS. The study is sponsored
by King Abdullah International Medical Research Center, Riyadh, Saudi
Arabia. Enrollment for this study began in November 2016, and has enrolled
thirteen patients as of Jan 24-2018.

Clinical and laboratory findings of the first imported case of middle east
respiratory syndrome coronavirus to the United States
Clinical Infectious Diseases 2014 59 :11 (1511 - 1518)
Translated Abstract
Background. The Middle East respiratory syndrome coronavirus (MERS-CoV) was
discovered September 2012 in the Kingdom of Saudi Arabia (KSA). The first
US case of MERS-CoV was confirmed on 2 May 2014. Methods. We summarize the
clinical symptoms and signs, laboratory and radiologic findings, and
MERS-CoV-specific tests. Results. The patient is a 65-year-old physician
who worked in a hospital in KSA where MERS-CoV patients were treated. His
illness onset included malaise, myalgias, and low-grade fever. He flew to
the United States on day of illness (DOI) 7. His first respiratory symptom,
a dry cough, developed on DOI 10. On DOI 11, he presented to an Indiana
hospital as dyspneic, hypoxic, and with a right lower lobe infiltrate on
chest radiography. On DOI 12, his serum tested positive by real-time
reverse transcription polymerase chain reaction (rRT-PCR) for MERS-CoV and
showed high MERS-CoV antibody titers, whereas his nasopharyngeal swab was
rRT-PCR negative. Expectorated sputum was rRT-PCR positive the following
day, with a high viral load (5.31 × 106 copies/mL). He was treated with
antibiotics, intravenous immunoglobulin, and oxygen by nasal cannula. He
was discharged on DOI 22. The genome sequence was similar (>99%) to other
known MERS-CoV sequences, clustering with those from KSA from June to July
2013. Conclusions. This patient had a prolonged nonspecific prodromal
illness before developing respiratory symptoms. Both sera and sputum were
rRT-PCR positive when nasopharyngeal specimens were negative. US clinicians
must be vigilant for MERS-CoV in patients with febrile and/or respiratory
illness with recent travel to the Arabian Peninsula, especially among
healthcare workers.

On Wed, Apr 22, 2020 at 8:47 AM Bensch, Anna <[log in to unmask]>

> Good morning,
> I have been running searches for the use of atorvastatin for the treatment
> or prevention of COVID-19 infection, however I am not receiving any
> results.  I have found a few articles on statins and COVID-19, but that's
> it.  Any luck that anyone may find something on this topic that I'm
> overlooking, or could share any resources that may help find something?  It
> could also be that this research isn't out there at this time.  Thanks!
> Best,
> Anna Bensch, MLIS
> Medical Librarian/CME Coordinator
> CentraState Healthcare System
> 901 West Main Street
> Freehold, NJ 07728
> [log in to unmask]<mailto:[log in to unmask]>
> [Description: New logo signature]
> The information contained in this e-mail message is intended only for the
> personal and confidential use of the intended recipient(s).  If you are not
> the intended recipient or an agent responsible for delivering the message
> to the intended recipient, you are hereby notified that you have received
> this document in error and that any review, dissemination, distribution, or
> copying of this message is strictly prohibited.  If you have received this
> communication in error, please notify me at the above e-mail or phone
> number, and delete the original message.